GlassScriptPhysician profile
Nicholas A Stathopoulos
NPI 1487642682
$11,686.75
in general payments reported to CMS, 2019-2025
23 companies · $2,706 in 2025
The $2,706 reported for 2025 was more than what 91% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,183 · 2020: $577 · 2021: $1,306 · 2022: $1,060 · 2023: $1,274 · 2024: $2,580 · 2025: $2,706.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,543 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,542.80 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,262.10 | 2019-2025 | Rocklatan, Argos, Eysuvis |
| Bausch & Lomb Americas INC. | $1,241.04 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $1,238.79 | 2019-2025 | Cequa, Xelpros |
| Johnson & Johnson Surgical Vision, INC. | $1,103.53 | 2019-2024 | Tecnis Simplicity |
| Novartis Pharmaceuticals Corporation | $1,042.92 | 2019-2023 | |
| Abbvie INC. | $911.72 | 2022-2025 | Durysta |
| Oyster Point Pharma, INC. | $693.38 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $522.69 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $505.29 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $396.44 | 2019-2021 | |
| Sight Sciences, INC. | $383.15 | 2019-2025 | Omni Surgical System, Sion Surgical Instrument |
| Glaukos Corporation | $327.85 | 2025 | Idosetr, Istent Inject, Istent Infinite |
| Amgen INC. | $196.19 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $182.55 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $124.99 | 2024 | Syfovre |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $124.57 | 2019-2021 | |
| Harrow Eye, LLC | $95.42 | 2024-2025 | Vevye, Iheezo |
| Shire North American Group INC | $78.67 | 2019 | |
| Biotissue Holdings INC. | $69.33 | 2024-2025 | |
| Ivantis, INC | $68.04 | 2020-2021 | |
| Thea Pharma INC. | $60.76 | 2023-2025 | Iyuzeh |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Ocular Therapeutix, INC. | $18.53 | 2025 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Stathopoulos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.